Theravance Biopharma Inc logo TBPH - Theravance Biopharma Inc

Inactive Ticker TBPH is not actively trading. Quotes and analytics may be stale.
Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 4
HOLD 10
SELL 3
STRONG
SELL 0
| PRICE TARGET: $17.00 DETAILS
HIGH: $17.00
LOW: $17.00
MEDIAN: $17.00
CONSENSUS: $17.00
DOWNSIDE: 0.18%

Stock News

CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial Analysis

CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial Analysis

CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) and Theravance Biopharma (NASDAQ: TBPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings. Profitability This table compares CASI Pharmaceuticals and

Oct 06, 2026 10:15 PM • defenseworld.net
Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast

Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast

vTv Therapeutics (NASDAQ: VTVT - Get Free Report) and Theravance Biopharma (NASDAQ: TBPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations. Earnings and Valuation This table compares vTv

Sep 28, 2026 02:15 AM • defenseworld.net
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Theravance and its board of directors violat.

Aug 15, 2026 03:07 AM • businesswire.com
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding restructuring and transaction costs) Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone payment 2 Quarter-end cash balance of $388 million and no debt DUBLIN, Aug. 10, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026. "During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the greatest value for Theravance Biopharma shareholders," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.

Aug 10, 2026 04:30 AM • prnewswire.com
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.

Jul 01, 2026 04:30 AM • seekingalpha.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

NEW YORK, June 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Theravance Biopharma, Inc. (NASDAQ: TBPH ) related to its sale to Zymeworks Inc. Under the terms of the proposed transaction, Theravance shareholders are expected to receive (i) $176.00 per share in cash and (ii) one contingent value right.

Jun 29, 2026 09:36 AM • prnewswire.com (Hide legal announcements)

Price Targets